<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mediators Inflamm</journal-id><journal-id journal-id-type="publisher-id">MI</journal-id><journal-title>Mediators of Inflammation</journal-title><issn pub-type="ppub">0962-9351</issn><issn pub-type="epub">1466-1861</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1155/2008/631414</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Comparison of C-Reactive Protein and Serum Amyloid A Protein in Septic Shock Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cicarelli</surname><given-names>Domingos Dias</given-names></name><xref ref-type="aff" rid="I1"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Vieira</surname><given-names>Joaquim Edson</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Bense&#x000f1;or</surname><given-names>F&#x000e1;bio Ely Martins</given-names></name><xref ref-type="aff" rid="I1"/></contrib></contrib-group><aff id="I1">Divis&#x000e3;o de Anestesia, Departamento de Cirurgia, Hospital das Cl&#x000ed;nicas da Faculdade de Medicina da Universidade de S&#x000e3;o Paulo, 01246-903 S&#x000e3;o Paulo, SP, Brazil</aff><author-notes><corresp id="cor1">*Domingos Dias Cicarelli: <email>dcicarelli@uol.com.br</email></corresp><fn fn-type="other"><p>Recommended by Freek Zijlstra</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>12</day><month>3</month><year>2008</year></pub-date><volume>2008</volume><elocation-id>631414</elocation-id><history><date date-type="received"><day>20</day><month>9</month><year>2007</year></date><date date-type="rev-recd"><day>14</day><month>11</month><year>2007</year></date><date date-type="accepted"><day>2</day><month>1</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Domingos Dias Cicarelli et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Septic shock is a severe inflammatory state caused by an infectious agent. Our purpose was to investigate serum amyloid A (SAA) protein and C-reactive protein (CRP) as inflammatory markers of septic shock patients. Here we evaluate 29 patients in postoperative period, with septic shock, in a prospective study developed in a surgical intensive care unit. All eligible patients were monitored over a 7-day period by sequential organ failure assessment (SOFA) score, daily CRP, SAA, and lactate measurements. CRP and SAA strongly correlated up to the fifth day of observation but were not good predictors of mortality in septic shock.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>Severe sepsis and septic shocks are a common cause of mortality in intensive care unit (ICU) [<xref ref-type="bibr" rid="B1">1</xref>]. They are a state of systemic inflammation in response to infectious agents that can lead to multiple organ system failure and death.</p><p>The systemic inflammatory response to infection involves the release of several mediators, which has led to the suggestion that some of these mediators could be used as markers of sepsis severity [<xref ref-type="bibr" rid="B2">2</xref>]. Among the acute-phase proteins that participate in the inflammatory response, C-reactive protein (CRP) is a component of the innate immune system that binds phosphocoline and recognizes some foreign pathogens as well as phospholipid constituents of damage cells; serum amyloid A (SAA) protein is an apolipoprotein that rapidly binds to high-density lipoprotein after their synthesis, influencing cholesterol metabolism during inflammatory states, causing adhesion and chemotaxis of phagocitic cells and lymphocytes [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>]. In some patients with chronic inflammation, the net effect of increased SAA production may be deleterious due to tissue deposition of its fragments and the development of systemic amyloidosis [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B5">5</xref>].</p><p>CRP and SAA display a similar pattern in most inflammatory diseases, reaching a maximum serum concentration about 24 hours after the inflammatory process sets in and slowly decreasing [<xref ref-type="bibr" rid="B6">6</xref>]. CRP is commonly used as a marker of an acute inflammatory state, produced by the liver in response to tissue injury or infection [<xref ref-type="bibr" rid="B7">7</xref>]. Its plasma concentration has been reported to parallel the clinical course of infection and the fall of the protein level indicates the resolution of infection [<xref ref-type="bibr" rid="B1">1</xref>]. SAA is the other major acute-phase protein in humans, with the earliest and highest increase rate of all acute-phase proteins, including CRP [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B8">8</xref>]. SAA concentrations usually parallel those of CRP. Some authors have been reported that SAA appears to be a clinically useful marker of inflammation in bacterial or viral infection likewise CRP [<xref ref-type="bibr" rid="B9">9</xref>]. Although some studies suggest that SAA is a more sensitive marker of inflammatory disease, assays for SAA are not widely available at present [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Until now, no study has compared daily CRP to SAA plasma concentrations in postoperative patients with septic shock, or has correlated them to the severity of patients represented by SOFA score. This study aimed to evaluate CRP and SAA measurements as markers of severity of septic shock patients during postoperative period.</p></sec><sec sec-type="section" id="sec2"><title>2. METHODS</title><p>This study was prospective at a surgical ICU. After approval by a local ethics committee, informed consent was obtained from patients or from their next of kin prior to enrollment [<xref ref-type="bibr" rid="B10">10</xref>]. Twenty-nine patients admitted into the surgical ICU of the Hospital das Cl&#x000ed;nicas da Faculdade de Medicina da Universidade de S&#x000e3;o Paulo had taken part in the study. Additional three patients were excluded after their next of kin gave up the signed consent. Patients with septic shock diagnosed during ICU stay were eligible for the study. We used the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definition of sepsis and septic shock [<xref ref-type="bibr" rid="B11">11</xref>]. Patients under 18 were excluded.</p><p>Severity of illness at the baseline was assessed based on the <italic>acute physiology and chronic health evaluation II</italic> (APACHE II) score [<xref ref-type="bibr" rid="B12">12</xref>]. Patients were assessed daily for 7 consecutive days using the <italic>sequential organ failure assessment</italic> score (SOFA) or until their discharge from the ICU when occurring in less than 7 days [<xref ref-type="bibr" rid="B13">13</xref>&#x02013;<xref ref-type="bibr" rid="B15">15</xref>]. C-reactive protein and serum amyloid A protein were also measured daily.</p><p>The patients received conventional therapy regarding antibiotic regimens, serial blood cultures (whenever that body temperature &#x0003e;38&#x000b0;C), and discharge criteria. Relevant clinical and laboratory tests were conducted daily throughout the study.</p><p>Blood samples for CRP and SAA dosage were thawed and assayed in batches in an automated analyzer (Behring Nephelometer Analyzer II, Dade Behring, Marburg, Denmark) for particle-enhanced immunonephelometry using commercial kits. The analytical sensitivity and accuracy for CRP was 0.0175&#x02009;mg/L (coefficient of variation (CV) 7,6%). The analytical sensitivity and accuracy for SAA was determined by the lower limit of the reference curve and thus depended on the concentration of the protein in SAA standard test (CV between 5.4% and 6.4%).</p><p>Statistical analysis was performed using commercial available package. Multiple logistic regressions were performed to test mortality of 7 or 28 days follow-up. A distribution analysis was made by the Kolmogorov-Smirnov test, Pearson correlation coefficients were determined, and repeated measures were tested by ANOVA. A <italic>P</italic> value &#x0003c; .05 was considered significant.</p></sec><sec sec-type="section" id="sec3"><title>3. RESULTS</title><p>The mean (&#x000b1;SD) age of the 29 patients was 65 &#x000b1; 13.9 years (range, 34 to 88 years). The study involved 13 males and 16 females (45%/55%). The APACHE II score of these patients was 19.8 &#x000b1; 4.5 (<xref ref-type="table" rid="tab1">Table 1</xref>). <xref ref-type="table" rid="tab2">Table 2</xref> represents the microbiological characteristics of the studied patients.</p><p>SOFA did not show increase from Day 0 to Day 7 of observation (<italic>P</italic> = .589, ANOVA) while CRP reduced significantly from Day 0 till the end of observation period (<italic>P</italic> &#x0003c; .001, ANOVA followed by Holm-Sidak test) as well as SAA (<italic>P</italic> &#x0003c; .001, ANOVA followed by Holm-Sidak test) (<xref ref-type="table" rid="tab3">Table 3</xref>).</p><p>CRP and SAA concentrations did not present any correlation with SOFA.</p><p>On the other hand, CRP and SAA have shown a good correlation from Day 0 till Day 5 (<xref ref-type="table" rid="tab4">Table 4</xref>).</p><p>Mortality of these patients in 7 days was 44.8% (13 in 29) and in 28 days was 65.5% (19 in 29). CRP and SAA concentrations were not associated with Day 7 mortality (<xref ref-type="table" rid="tab5">Table 5</xref>).</p><p>CRP and SAA concentrations evolution during the first week comparing survivors and nonsurvivors were not statistically significant (Figures <xref ref-type="fig" rid="fig1">1</xref> and <xref ref-type="fig" rid="fig2">2</xref>).</p></sec><sec sec-type="section" id="sec4"><title>4. DISCUSSION</title><p>The present study revealed significant positive correlation between SAA and CRP in postoperative septic shock patients. SOFA or APACHE II did not correlate with those serum measurements. Neither marker nor index was associated with mortality rate.</p><p>SAA has been considered by some authors to be equivalent to CRP in patients with bacterial infectious diseases in clinical practice [<xref ref-type="bibr" rid="B16">16</xref>]. Other authors suggest that SAA is a more sensitive marker than CRP in infections with low inflammatory activity (including many viral infections) and in other clinical conditions, especially those involving the lung tissue [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>]. Yet other studies have confirmed the role of SAA and CRP in diagnosis and management of neonatal infections [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B18">18</xref>].</p><p>The patterns of cytokine production and the acute-phase response differ for different inflammatory conditions. Acute-phase changes reflect the presence and intensity of inflammation and they have long been used as a clinical guide for diagnosis and management. Among patients with plasma CRP concentrations higher than 10&#x02009;mg/dL, 80-to-85 percent have bacterial infections [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B19">19</xref>]. In our study, all the patients were in septic shock with documented infection. We could observe that all patients during the 7-day period of observation presented plasma CRP concentrations greater than 10&#x02009;mg/dL, according to results that Gabay et al. in a review article cited [<xref ref-type="bibr" rid="B4">4</xref>]. This fact could indicate that sepsis is secondary to bacterial infections. In relation to plasma SAA concentrations, a cutoff value has not been determined from previous studies. We observed a level higher or closer to 20&#x02009;mg/dL, but more studies were needed to find a cutoff value for SAA as an early diagnostic tool for patients with infection.</p><p>We did not observe difference between CRP and SAA early (Day 1) concentrations in patients who survived compared with those who died. Other authors have found that these proteins were not prognostic markers in patients with septic shock [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B19">19</xref>]. This fact is in concordance with our results.</p><p>Previous reports have observed that CRP level was associated with organ failure in critically ill patients, although not specifically under septic shock [<xref ref-type="bibr" rid="B14">14</xref>]. This study could not find any good correlation between CRP or SAA with SOFA, probably not in agreement with other authors [<xref ref-type="bibr" rid="B20">20</xref>]. They believe that both CRP and SAA are good markers of organ dysfunction, considering the established diagnostic of septic shock.</p><p>Study limitations are attributed primarily to the small sample size and the age of the patients that could influence CRP levels. Some authors believe that the older the patient is, the higher CRP levels that can be observed [<xref ref-type="bibr" rid="B21">21</xref>].</p><p>In conclusion, SAA protein and CRP are strongly correlated, but were not good predictors of organ dysfunction and mortality in septic shock.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luzzani</surname><given-names>A</given-names></name><name><surname>Polati</surname><given-names>E</given-names></name><name><surname>Dorizzi</surname><given-names>R</given-names></name><name><surname>Rungatscher</surname><given-names>A</given-names></name><name><surname>Pavan</surname><given-names>R</given-names></name><name><surname>Merlini</surname><given-names>A</given-names></name></person-group><article-title>Comparison of procalcitonin and C-reactive protein as markers of sepsis</article-title><source><italic>Critical Care Medicine</italic></source><year>2003</year><volume>31</volume><issue>6</issue><fpage>1737</fpage><lpage>1741</lpage><pub-id pub-id-type="pmid">12794413</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Enguix</surname><given-names>A</given-names></name><name><surname>Rey</surname><given-names>C</given-names></name><name><surname>Concha</surname><given-names>A</given-names></name><name><surname>Medina</surname><given-names>A</given-names></name><name><surname>Coto</surname><given-names>D</given-names></name><name><surname>Di&#x000e9;guez</surname><given-names>MA</given-names></name></person-group><article-title>Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children</article-title><source><italic>Intensive Care Medicine</italic></source><year>2001</year><volume>27</volume><issue>1</issue><fpage>211</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">11280637</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>H</given-names></name><name><surname>Fellowes</surname><given-names>R</given-names></name><name><surname>Coade</surname><given-names>S</given-names></name><name><surname>Woo</surname><given-names>P</given-names></name></person-group><article-title>Human serum amyloid A has cytokine-like properties</article-title><source><italic>Scandinavian Journal of Immunology</italic></source><year>1998</year><volume>48</volume><issue>4</issue><fpage>410</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">9790312</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabay</surname><given-names>C</given-names></name><name><surname>Kushner</surname><given-names>I</given-names></name></person-group><article-title>Acute-phase proteins and other systemic responses to inflammation</article-title><source><italic>New England Journal of Medicine</italic></source><year>1999</year><volume>340</volume><issue>6</issue><fpage>448</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">9971870</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Urieli-Shoval</surname><given-names>S</given-names></name><name><surname>Linke</surname><given-names>RP</given-names></name><name><surname>Matzner</surname><given-names>Y</given-names></name></person-group><article-title>Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states</article-title><source><italic>Current Opinion in Hematology</italic></source><year>2000</year><volume>7</volume><issue>1</issue><fpage>64</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">10608507</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cicarelli</surname><given-names>LM</given-names></name><name><surname>Perroni</surname><given-names>AG</given-names></name><name><surname>Zugaib</surname><given-names>M</given-names></name><name><surname>de Albuquerque</surname><given-names>PB</given-names></name><name><surname>Campa</surname><given-names>A</given-names></name></person-group><article-title>Maternal and cord blood levels of serum amyloid A, C-reactive protein, tumor necrosis factor-<italic>&#x003b1;</italic>, interleukin-1<italic>&#x003b2;</italic>, and interleukin-8 during and after delivery</article-title><source><italic>Mediators of Inflammation</italic></source><year>2005</year><volume>2005</volume><issue>2</issue><fpage>96</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">16030392</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ugarte</surname><given-names>H</given-names></name><name><surname>Silva</surname><given-names>E</given-names></name><name><surname>Mercan</surname><given-names>D</given-names></name><name><surname>De Mendon&#x000e7;a</surname><given-names>A</given-names></name><name><surname>Vincent</surname><given-names>J-L</given-names></name></person-group><article-title>Procalcitonin used as a marker of infection in the intensive care unit</article-title><source><italic>Critical Care Medicine</italic></source><year>1999</year><volume>27</volume><issue>3</issue><fpage>498</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">10199528</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnon</surname><given-names>S</given-names></name><name><surname>Litmanovitz</surname><given-names>I</given-names></name><name><surname>Regev</surname><given-names>R</given-names></name><name><surname>Lis</surname><given-names>M</given-names></name><name><surname>Shainkin-Kestenbaum</surname><given-names>R</given-names></name><name><surname>Dolfin</surname><given-names>T</given-names></name></person-group><article-title>Serum amyloid A protein in the early detection of late-onset bacterial sepsis in preterm infants</article-title><source><italic>Journal of Perinatal Medicine</italic></source><year>2002</year><volume>30</volume><issue>4</issue><fpage>329</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">12235722</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Sonoda</surname><given-names>S</given-names></name><name><surname>Urano</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Okada</surname><given-names>M</given-names></name></person-group><article-title>Monitoring both serum amyloid protein A and C-reactive protein as inflammatory markers in infectious diseases</article-title><source><italic>Clinical Chemistry</italic></source><year>1993</year><volume>39</volume><issue>2</issue><fpage>293</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">8381732</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reade</surname><given-names>MC</given-names></name><name><surname>Young</surname><given-names>JD</given-names></name></person-group><article-title>Consent for observational studies in critical care: time to open Pandora's Box</article-title><source><italic>Anaesthesia</italic></source><year>2003</year><volume>58</volume><issue>1</issue><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">12492660</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>MM</given-names></name><name><surname>Fink</surname><given-names>MP</given-names></name><name><surname>Marshall</surname><given-names>JC</given-names></name><etal/></person-group><article-title>2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference</article-title><source><italic>Intensive Care Medicine</italic></source><year>2003</year><volume>29</volume><issue>4</issue><fpage>530</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">12664219</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reny</surname><given-names>J-L</given-names></name><name><surname>Vuagnat</surname><given-names>A</given-names></name><name><surname>Ract</surname><given-names>C</given-names></name><name><surname>Benoit</surname><given-names>M-O</given-names></name><name><surname>Safar</surname><given-names>M</given-names></name><name><surname>Fagon</surname><given-names>J-Y</given-names></name></person-group><article-title>Diagnosis and follow-up of infections in intensive care patients: value of C-reactive protein compared with other clinical and biological variables</article-title><source><italic>Critical Care Medicine</italic></source><year>2002</year><volume>30</volume><issue>3</issue><fpage>529</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">11990910</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hulley</surname><given-names>SB</given-names></name><name><surname>Cummings</surname><given-names>SR</given-names></name></person-group><source><italic>Designing Clinical Research</italic></source><year>1988</year><edition>1st edition</edition><publisher-loc>Philadelphia, Pa, USA</publisher-loc><publisher-name>Williams &#x00026; Wilkins</publisher-name></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lobo</surname><given-names>SMA</given-names></name><name><surname>Lobo</surname><given-names>FRM</given-names></name><name><surname>Bota</surname><given-names>DP</given-names></name><etal/></person-group><article-title>C-reactive protein levels correlate with mortality and organ failure in critically ill patients</article-title><source><italic>Chest</italic></source><year>2003</year><volume>123</volume><issue>6</issue><fpage>2043</fpage><lpage>2049</lpage><pub-id pub-id-type="pmid">12796187</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>JC</given-names></name><name><surname>Vincent</surname><given-names>J-L</given-names></name><name><surname>Fink</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Measures, markers, and mediators: toward a staging system for clinical sepsis. A Report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000</article-title><source><italic>Critical Care Medicine</italic></source><year>2003</year><volume>31</volume><issue>5</issue><fpage>1560</fpage><lpage>1567</lpage><pub-id pub-id-type="pmid">12771633</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lannerg&#x000e5;rd</surname><given-names>A</given-names></name><name><surname>Larsson</surname><given-names>A</given-names></name><name><surname>Kragsbjerg</surname><given-names>P</given-names></name><name><surname>Friman</surname><given-names>G</given-names></name></person-group><article-title>Correlations between serum amyloid A protein and C-reactive protein in infectious diseases</article-title><source><italic>Scandinavian Journal of Clinical and Laboratory Investigation</italic></source><year>2003</year><volume>63</volume><issue>4</issue><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">12940634</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huttunen</surname><given-names>T</given-names></name><name><surname>Teppo</surname><given-names>A-M</given-names></name><name><surname>Lupisan</surname><given-names>S</given-names></name><name><surname>Ruutu</surname><given-names>P</given-names></name><name><surname>Nohynek</surname><given-names>H</given-names></name></person-group><article-title>Correlation between the severity of infectious diseases in children and the ratio of serum amyloid A protein and C-reactive protein</article-title><source><italic>Scandinavian Journal of Infectious Diseases</italic></source><year>2003</year><volume>35</volume><issue>8</issue><fpage>488</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">14514149</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pizzini</surname><given-names>C</given-names></name><name><surname>Mussap</surname><given-names>M</given-names></name><name><surname>Plebani</surname><given-names>M</given-names></name><name><surname>Fanos</surname><given-names>V</given-names></name></person-group><article-title>C-reactive protein and serum amyloid A protein in neonatal infections</article-title><source><italic>Scandinavian Journal of Infectious Diseases</italic></source><year>2000</year><volume>32</volume><issue>3</issue><fpage>229</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">10879591</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suprin</surname><given-names>E</given-names></name><name><surname>Camus</surname><given-names>C</given-names></name><name><surname>Gacouin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Procalcitonin: a valuable indicator of infection in a medical ICU?</article-title><source><italic>Intensive Care Medicine</italic></source><year>2000</year><volume>26</volume><issue>9</issue><fpage>1232</fpage><lpage>1238</lpage><pub-id pub-id-type="pmid">11089747</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castelli</surname><given-names>GP</given-names></name><name><surname>Pognani</surname><given-names>C</given-names></name><name><surname>Meisner</surname><given-names>M</given-names></name><name><surname>Stuani</surname><given-names>A</given-names></name><name><surname>Bellomi</surname><given-names>D</given-names></name><name><surname>Sgarbi</surname><given-names>L</given-names></name></person-group><article-title>Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction</article-title><source><italic>Critical Care</italic></source><year>2004</year><volume>8</volume><issue>4</issue><fpage>R234</fpage><lpage>R242</lpage><pub-id pub-id-type="pmid">15312223</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wener</surname><given-names>MH</given-names></name><name><surname>Daum</surname><given-names>PR</given-names></name><name><surname>McQuillan</surname><given-names>GM</given-names></name></person-group><article-title>The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration</article-title><source><italic>Journal of Rheumatology</italic></source><year>2000</year><volume>27</volume><issue>10</issue><fpage>2351</fpage><lpage>2359</lpage><pub-id pub-id-type="pmid">11036829</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>CRP evolution of survivors and nonsurvivors during the first week (NS). NS: not statistically significant.</p></caption><graphic xlink:href="MI2008-631414.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>SAA evolution of survivors and nonsurvivors during the first week (NS). NS: not statistically significant.</p></caption><graphic xlink:href="MI2008-631414.002"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"><bold>Characteristics</bold></th><th align="center" rowspan="1" colspan="1"><bold>n = 29</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">65 &#x000b1; 13.9</td></tr><tr><td rowspan="1" colspan="1">Male sex</td><td align="center" rowspan="1" colspan="1">45%</td></tr><tr><td rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">63.5 &#x000b1; 11.7</td></tr><tr><td rowspan="1" colspan="1">APACHE II score</td><td align="center" rowspan="1" colspan="1">19.8 &#x000b1; 4.5</td></tr><tr><td rowspan="1" colspan="1">SOFA score</td><td align="center" rowspan="1" colspan="1">9.6 &#x000b1; 2.3</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1"><bold>Prior or preexisting conditions</bold></td><td align="center" rowspan="1" colspan="1">(%)</td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">31</td></tr><tr><td rowspan="1" colspan="1">Myocardial infarction</td><td align="center" rowspan="1" colspan="1">13.7</td></tr><tr><td rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">13.7</td></tr><tr><td rowspan="1" colspan="1">Liver disease</td><td align="center" rowspan="1" colspan="1">6.9</td></tr><tr><td rowspan="1" colspan="1">COPD</td><td align="center" rowspan="1" colspan="1">6.9</td></tr><tr><td rowspan="1" colspan="1">Cancer</td><td align="center" rowspan="1" colspan="1">20.7</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1"><bold>Surgery</bold></td><td align="center" rowspan="1" colspan="1">(%)</td></tr><tr><td rowspan="1" colspan="1">Multiple trauma (excluding head trauma)</td><td align="center" rowspan="1" colspan="1">3.4</td></tr><tr><td rowspan="1" colspan="1">Gastrointestinal surgery</td><td align="center" rowspan="1" colspan="1">75.9</td></tr><tr><td rowspan="1" colspan="1">Major vascular surgery</td><td align="center" rowspan="1" colspan="1">6.9</td></tr><tr><td rowspan="1" colspan="1">Thoracic surgery</td><td align="center" rowspan="1" colspan="1">3.4</td></tr><tr><td rowspan="1" colspan="1">Urologic surgery</td><td align="center" rowspan="1" colspan="1">10.4</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1"><bold>Other indicators of disease severity</bold></td><td align="center" rowspan="1" colspan="1"><bold>(days)</bold></td></tr><tr><td rowspan="1" colspan="1">Mechanical ventilation</td><td align="center" rowspan="1" colspan="1">4.0 &#x000b1; 3.2</td></tr><tr><td rowspan="1" colspan="1">Shock (use of vasopressor)</td><td align="center" rowspan="1" colspan="1">4.2 &#x000b1; 1.9</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p><italic>APACHE</italic>: acute physiology and chronic health evaluation, <italic>SOFA</italic>: sequential organ failure assessment, COPD: chronic obstructive pulmonary disease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Microbiological characteristics of patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Patient</th><th rowspan="1" colspan="1">Surgery/phatology</th><th rowspan="1" colspan="1">Antibiotics</th><th rowspan="1" colspan="1">Type of organism</th><th rowspan="1" colspan="1">Type of culture</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Cholecistectomy/biliary abscess</td><td rowspan="1" colspan="1">Vanco + cefepime</td><td rowspan="1" colspan="1">S. aureus</td><td rowspan="1" colspan="1">Abscess culture</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Empyema pleural drainage</td><td rowspan="1" colspan="1">Ceftriaxone + clindamycin</td><td rowspan="1" colspan="1">S. pyogenes</td><td rowspan="1" colspan="1">Pleural abscess culture</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Cholecistectomy/biliary abscess</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">Negative cultures</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">Cystectomy/pyuria</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">Negative cultures</td></tr><tr><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Aortic bypass/leg amputation</td><td rowspan="1" colspan="1">Ceftazidime + clindamycin</td><td rowspan="1" colspan="1">P. aeruginosa</td><td rowspan="1" colspan="1">Surgical site culture</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Colectomy/cavity contamination</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">Negative cultures</td></tr><tr><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">Calcaneal exposure fracture</td><td rowspan="1" colspan="1">Ciprofloxacin</td><td rowspan="1" colspan="1">E. faecalis</td><td rowspan="1" colspan="1">Surgical site culture</td></tr><tr><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">Pyonephrosis drainage</td><td rowspan="1" colspan="1">Ceftriaxone</td><td rowspan="1" colspan="1">K. pneumoniae</td><td rowspan="1" colspan="1">Urinary culture</td></tr><tr><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">Sigmoidectomy</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td rowspan="1" colspan="1">A. baumanii</td><td rowspan="1" colspan="1">Blood culture</td></tr><tr><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">Hemicolectomy</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td rowspan="1" colspan="1">Candida albicans</td><td rowspan="1" colspan="1">Blood culture</td></tr><tr><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">Enterectomy/mesenteric ischemia</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">Negative cultures</td></tr><tr><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">Pancreatic-duodenal resection</td><td rowspan="1" colspan="1">Ceftriaxone</td><td rowspan="1" colspan="1">Serratia marcesens</td><td rowspan="1" colspan="1">BAL</td></tr><tr><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">Pancreatic-duodenal resection</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td rowspan="1" colspan="1">S. coag negative</td><td rowspan="1" colspan="1">Blood culture</td></tr><tr><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">Retroperitoneal abscess drainage</td><td rowspan="1" colspan="1">Cefepime + vanco + imipenem</td><td rowspan="1" colspan="1">P. aeruginosa</td><td rowspan="1" colspan="1">Blood culture</td></tr><tr><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">Abdominal aneurysm repair</td><td rowspan="1" colspan="1">Vanco + imipenem</td><td rowspan="1" colspan="1">S. aureus</td><td rowspan="1" colspan="1">Blood culture</td></tr><tr><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">Sigmoidectomy/perforative lesion</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td rowspan="1" colspan="1">Serratia marcesens</td><td rowspan="1" colspan="1">Ascite culture</td></tr><tr><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">Colectomy</td><td rowspan="1" colspan="1">Cefepime + vanco</td><td rowspan="1" colspan="1">S. aureus</td><td rowspan="1" colspan="1">Blood culture</td></tr><tr><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">Gastric ulcer</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">Negative cultures</td></tr><tr><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">Cholecistectomy</td><td rowspan="1" colspan="1">Cipro + metronidazole</td><td rowspan="1" colspan="1">Escherichia coli</td><td rowspan="1" colspan="1">Urinary culture</td></tr><tr><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">Hemicolectomy</td><td rowspan="1" colspan="1">Cefepime + vanco + metro</td><td rowspan="1" colspan="1">E. cloacae</td><td rowspan="1" colspan="1">Blood culture</td></tr><tr><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">Enterectomy/cavity contamination</td><td rowspan="1" colspan="1">Vanco + imipenem</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">Negative cultures</td></tr><tr><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">Colectomy</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td rowspan="1" colspan="1">A. baumanii</td><td rowspan="1" colspan="1">Blood culture</td></tr><tr><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">Colectomy</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td rowspan="1" colspan="1">P. aeruginosa</td><td rowspan="1" colspan="1">Blood culture</td></tr><tr><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">Enterectomy/cavity contamination</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">Negative cultures</td></tr><tr><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">Cervical abscess drainage</td><td rowspan="1" colspan="1">Imipenem + vanco + metro</td><td rowspan="1" colspan="1">K. pneumoniae</td><td rowspan="1" colspan="1">Blood culture</td></tr><tr><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">Sigmoidectomy/perforative lesion</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td rowspan="1" colspan="1">P. aeruginosa</td><td rowspan="1" colspan="1">Blood culture</td></tr><tr><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">Sigmoidectomy</td><td rowspan="1" colspan="1">Cefepime + metronidazole</td><td rowspan="1" colspan="1">S. aureus</td><td rowspan="1" colspan="1">Blood culture</td></tr><tr><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">Pyonephrosis drainage</td><td rowspan="1" colspan="1">Cefepime + metronidazole</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">Negative cultures</td></tr><tr><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">Colectomy</td><td rowspan="1" colspan="1">Ceftriaxone + metronidazole</td><td rowspan="1" colspan="1">P. aeruginosa</td><td rowspan="1" colspan="1">BAL</td></tr></tbody></table><table-wrap-foot><fn id="TF2"><p>Vanco: vancomycin, Cipro: ciprofloxacin, Metro: metronidazole, S. aureus: Staphylococcus aureus, S. pyogenes: Streptococcus pyogenes, P. aeruginosa: Pseudomonas aeruginosa, E. faecalis: Enterobacter faecalis, K. pneumoniae: Klebsiella pneumoniae, A. baumanii: Acinetobacter baumanii, S. coag negative: Staphylococcus coagulase negative, E. cloacae: Enterobacter cloacae, BAL: bronchoalveolar lavage.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>SOFA, CRP, and SAA during the study period (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Day 0</th><th align="center" rowspan="1" colspan="1">Day 1</th><th align="center" rowspan="1" colspan="1">Day 2</th><th align="center" rowspan="1" colspan="1">Day 3</th><th align="center" rowspan="1" colspan="1">Day 4</th><th align="center" rowspan="1" colspan="1">Day 5</th><th align="center" rowspan="1" colspan="1">Day 6</th><th align="center" rowspan="1" colspan="1">Day 7</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">SOFA</td><td align="center" rowspan="1" colspan="1">9.6 &#x000b1; 2.3</td><td align="center" rowspan="1" colspan="1">10 &#x000b1; 2.6</td><td align="center" rowspan="1" colspan="1">9.4 &#x000b1; 4.1 </td><td align="center" rowspan="1" colspan="1">9.8 &#x000b1; 4.4</td><td align="center" rowspan="1" colspan="1">9.4 &#x000b1; 4.2</td><td align="center" rowspan="1" colspan="1">9.9 &#x000b1; 3.7</td><td align="center" rowspan="1" colspan="1">8.7 &#x000b1; 4.1</td><td align="center" rowspan="1" colspan="1">8.6 &#x000b1; 3.5</td></tr><tr><td rowspan="1" colspan="1">CRP</td><td align="center" rowspan="1" colspan="1">19.8 &#x000b1; 8.4</td><td align="center" rowspan="1" colspan="1">20.9 &#x000b1; 9.1</td><td align="center" rowspan="1" colspan="1">16.3 &#x000b1; 6.2</td><td align="center" rowspan="1" colspan="1">13.2 &#x000b1; 5.9</td><td align="center" rowspan="1" colspan="1">11.8 &#x000b1; 7.7</td><td align="center" rowspan="1" colspan="1">12.7 &#x000b1; 11.2</td><td align="center" rowspan="1" colspan="1">11.9 &#x000b1; 8.3</td><td align="center" rowspan="1" colspan="1">10.0 &#x000b1; 4.4</td></tr><tr><td rowspan="1" colspan="1">SAA</td><td align="center" rowspan="1" colspan="1">47 &#x000b1; 39.8</td><td align="center" rowspan="1" colspan="1">37.2 &#x000b1; 28.1</td><td align="center" rowspan="1" colspan="1">29 &#x000b1; 21.48</td><td align="center" rowspan="1" colspan="1">22.7 &#x000b1; 18.4</td><td align="center" rowspan="1" colspan="1">18.6 &#x000b1; 20.8</td><td align="center" rowspan="1" colspan="1">24.7 &#x000b1; 25.8</td><td align="center" rowspan="1" colspan="1">22.2 &#x000b1; 20.5</td><td align="center" rowspan="1" colspan="1">21.7 &#x000b1; 16.8</td></tr></tbody></table><table-wrap-foot><fn id="TF3"><p>SOFA: sequential organ failure assessment, CRP: C-reactive protein, SAA: serum amyloid A. ANOVA. Equal variance test: SOFA <italic>P</italic> = .956, CRP <italic>P</italic> = .062, SAA <italic>P</italic> = .055.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" position="float"><label>Table 4</label><caption><p>Pearson coefficient for SAA and CPR.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic>r</italic></th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Day 0</td><td align="center" rowspan="1" colspan="1">0.682</td><td align="center" rowspan="1" colspan="1">.0001</td></tr><tr><td rowspan="1" colspan="1">Day 1</td><td align="center" rowspan="1" colspan="1">0.660</td><td align="center" rowspan="1" colspan="1">.0004</td></tr><tr><td rowspan="1" colspan="1">Day 2</td><td align="center" rowspan="1" colspan="1">0.464</td><td align="center" rowspan="1" colspan="1">.034</td></tr><tr><td rowspan="1" colspan="1">Day 3</td><td align="center" rowspan="1" colspan="1">0.529</td><td align="center" rowspan="1" colspan="1">.024</td></tr><tr><td rowspan="1" colspan="1">Day 4</td><td align="center" rowspan="1" colspan="1">0.651</td><td align="center" rowspan="1" colspan="1">.0062</td></tr><tr><td rowspan="1" colspan="1">Day 5</td><td align="center" rowspan="1" colspan="1">0.778</td><td align="center" rowspan="1" colspan="1">.0028</td></tr><tr><td rowspan="1" colspan="1">Day 6</td><td align="center" rowspan="1" colspan="1">0.578</td><td align="center" rowspan="1" colspan="1">.628</td></tr><tr><td rowspan="1" colspan="1">Day 7</td><td align="center" rowspan="1" colspan="1">0.081</td><td align="center" rowspan="1" colspan="1">.822</td></tr></tbody></table></table-wrap><table-wrap id="tab5" position="float"><label>Table 5</label><caption><p>Maximum likelihood, Wald statistic (<italic>P</italic>-value).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">APACHE II</th><th align="center" rowspan="1" colspan="1">SOFA</th><th align="center" rowspan="1" colspan="1">CPR</th><th align="center" rowspan="1" colspan="1">SAA</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Day 0</td><td align="center" rowspan="1" colspan="1">3.46 (.06)</td><td align="center" rowspan="1" colspan="1">2.46 (.11)</td><td align="center" rowspan="1" colspan="1">0.02 (.89)</td><td align="center" rowspan="1" colspan="1">1.91 (.17)</td></tr><tr><td rowspan="1" colspan="1">Day 1</td><td align="center" rowspan="1" colspan="1">3.06 (.08)</td><td align="center" rowspan="1" colspan="1">3.50 (.06)</td><td align="center" rowspan="1" colspan="1">1.01 (.31)</td><td align="center" rowspan="1" colspan="1">0.03 (.86)</td></tr><tr><td rowspan="1" colspan="1">Day 3</td><td align="center" rowspan="1" colspan="1">0.00 (.98)</td><td align="center" rowspan="1" colspan="1">0.00 (.98)</td><td align="center" rowspan="1" colspan="1">0.00 (.98)</td><td align="center" rowspan="1" colspan="1">0.00 (.98)</td></tr></tbody></table></table-wrap></floats-wrap></article> 